The financials
BioMarin Pharmaceutical Inc. by the numbers
BioMarin Pharmaceutical Inc. (BMRN) reported revenue of $766M in Q1 2026 (quarter ended March 31, 2026), up 2.8% from the same quarter a year earlier. That came with a gross margin of 75% and net income of $106M (14% of revenue). For the full year FY2025, revenue was $3.22B (+13% year on year) and net income $349M. Its largest product in 2026-Q1 was VOXZOGO at $220M, 29% of the disclosed total, just ahead of VIMIZIM at 27%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $766M | $745M | +2.8% |
| Gross profit | $571M | $594M | −3.8% |
| Operating income | $130M | $224M | −42% |
| Net income | $106M | $186M | −43% |
| Diluted EPS | $0.54 | $0.95 | −43% |
| Product | Revenue | Share |
|---|---|---|
| VOXZOGO | $220M | 29% |
| VIMIZIM | $210M | 27% |
| NAGLAZYME | $130M | 17% |
| PALYNZIQ | $90M | 12% |
| BRINEURA | $47M | 6.1% |
| ALDURAZYME | $37M | 4.8% |
| KUVAN | $24M | 3.1% |
| Royalty And Other | $6.1M | 0.8% |
| ROCTAVIAN | $2.6M | 0.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $766.2M (-1.3%)
BRINEURA grew +17% year on yearROCTAVIAN -75% year on year
Segment Latestquarter on quarteryear on year
- VOXZOGO$219.9M$219.9MQoQ +0.68%year on year +2.9%+0.68%+2.9%
- VIMIZIM$210.2M$210.2MQoQ +15%year on year +12%+15%+12%
- NAGLAZYME$130.1M$130.1MQoQ +6.6%year on year +14%+6.6%+14%
- PALYNZIQ$89.6M$89.6MQoQ -18%year on year -4.0%-18%-4.0%
- BRINEURA$47.1M$47.1MQoQ -1.8%year on year +17%-1.8%+17%
- ALDURAZYME$36.7M$36.7MQoQ -32%year on year -25%-32%-25%
- KUVAN$23.9M$23.9MQoQ -0.60%year on year -5.0%-0.60%-5.0%
- Royalty And Other$6.1M$6.1MQoQ -60%year on year -42%-60%-42%
- ROCTAVIAN$2.6M$2.6MQoQ -17%year on year -75%-17%-75%